|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alberg AJ, Brock MV, Ford JG, Samet JM and
Spivack SD: Epidemiology of lung cancer: Diagnosis and management
of lung cancer, 3rd ed: American college of chest physicians
evidence-based clinical practice guidelines. Chest. 143 5
Suppl:e1S–e29S. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ,
Dobelbower M, et al: Non-small cell lung cancer, version 5.2017,
NCCN clinical practice guidelines in oncology. J Natl Compr Canc
Netw. 15:504–535. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clark GM: Prognostic factors versus
predictive factors: Examples from a clinical trial of erlotinib.
Mol Oncol. 1:406–412. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brown T, Pilkington G, Bagust A, Boland A,
Oyee J, Tudur-Smith C, Blundell M, Lai M, Saborido Martin C,
Greenhalgh J, et al: Clinical effectiveness and cost-effectiveness
of first-line chemotherapy for adult patients with locally advanced
or metastatic non-small cell lung cancer: A systematic review and
economic evaluation. Health Technol Assess. 17:1–278. 2013.
View Article : Google Scholar
|
|
6
|
Greenhalgh J, Dwan K, Boland A, Bates V,
Vecchio F, Dundar Y, Jain P and Green JA: First-line treatment of
advanced epidermal growth factor receptor (EGFR) mutation positive
non-squamous non-small cell lung cancer. Cochrane Database Syst
Rev: CD010383. 2016. View Article : Google Scholar
|
|
7
|
Palma JF, Das P and Liesenfeld O: Lung
cancer screening: Utility of molecular applications in conjunction
with low-dose computed tomography guidelines. Expert Rev Mol Diagn.
16:435–447. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tomita M, Shimizu T, Hara M, Ayabe T and
Onitsuka T: Impact of preoperative hemoglobin level on survival of
non-small cell lung cancer patients. Anticancer Res. 28:1947–1950.
2008.PubMed/NCBI
|
|
9
|
Gauthier I, Ding K, Winton T, Shepherd FA,
Livingston R, Johnson DH, Rigas JR, Whitehead M, Graham B and
Seymour L: Impact of hemoglobin levels on outcomes of adjuvant
chemotherapy in resected non-small cell lung cancer: The JBR.10
trial experience. Lung Cancer. 55:357–363. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aoe K, Hiraki A, Maeda T, Katayama H,
Fujiwara K, Tabata M, Kiura K, Ueoka H and Tanimoto M: Serum
hemoglobin level determined at the first presentation is a poor
prognostic indicator in patients with lung cancer. Intern Med.
44:800–804. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Trufelli DC, Moraes TV, Lima AA and Giglio
AD: Epidemiological profile and prognostic factors in patients with
lung cancer. Rev Assoc Med Bras (1992). 62:428–433. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Watine J: Blood hemoglobin as an
independent prognostic factor in surgically resected stages I and
II non-small cell lung cancer patients. Ann Thorac Surg.
73:2034–2035, Author reply 2035. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kay FU, Kandathil A, Batra K, Saboo SS,
Abbara S and Rajiah P: Revisions to the tumor, node, metastasis
staging of lung cancer (8th edition): Rationale, radiologic
findings and clinical implications. World J Radiol. 9:269–279.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schag CC, Heinrich RL and Ganz PA:
Karnofsky performance status revisited: Reliability, validity, and
guidelines. J Clin Oncol. 2:187–193. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Langendijk H, de Jong J, Wanders R, Lambin
P and Slotman B: The importance of pre-treatment haemoglobin level
in inoperable non-small cell lung carcinoma treated with radical
radiotherapy. Radiother Oncol. 67:321–325. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Holgersson G, Sandelin M, Hoye E,
Bergström S, Henriksson R, Ekman S, Nyman J, Helsing M, Friesland
S, Holgersson M, et al: Swedish lung cancer radiation study group:
The prognostic value of anaemia, thrombocytosis and leukocytosis at
time of diagnosis in patients with non-small cell lung cancer. Med
Oncol. 29:3176–3182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ray-Coquard I, Morère JF, Scotté F, Cals L
and Antoine EC: Management of anemia in advanced breast and lung
cancer patients in daily practice: Results of a French survey. Adv
Ther. 29:124–133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vannella L, Lahner E, Osborn J and
Annibale B: Systematic review: Gastric cancer incidence in
pernicious anaemia. Aliment Pharmacol Ther. 37:375–382. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Altman AD, Liu XQ, Nelson G, Chu P, Nation
J and Ghatage P: The effects of anemia and blood transfusion on
patients with stage III–IV ovarian cancer. Int J Gynecol Cancer.
23:1569–1576. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Banzet S, Sanchez H, Chapot R, Bigard X,
Vaulont S and Koulmann N: Interleukin-6 contributes to hepcidin
mRNA increase in response to exercise. Cytokine. 58:158–161. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun CC, Vaja V, Babitt JL and Lin HY:
Targeting the hepcidin-ferroportin axis to develop new treatment
strategies for anemia of chronic disease and anemia of
inflammation. Am J Hematol. 87:392–400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu Y, Antony S, Meitzler JL and Doroshow
JH: Molecular mechanisms underlying chronic inflammation-associated
cancers. Cancer Lett. 345:164–173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Aapro M, Jelkmann W, Constantinescu SN and
Leyland-Jones B: Effects of erythropoietin receptors and
erythropoiesis-stimulating agents on disease progression in cancer.
Br J Cancer. 106:1249–1258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tefferi A, Hudgens S, Mesa R, Gale RP,
Verstovsek S, Passamonti F, Cervantes F, Rivera C, Tencer T and
Khan ZM: Use of the functional assessment of cancer therapy-anemia
in persons with myeloproliferative neoplasm-associated
myelofibrosis and anemia. Clin Ther. 36:560–566. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schwab LP, Peacock DL, Majumdar D, Ingels
JF, Jensen LC, Smith KD, Cushing RC and Seagroves TN:
Hypoxia-inducible factor 1α promotes primary tumor growth and
tumor-initiating cell activity in breast cancer. Breast Cancer Res.
14:R62012. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li S, Meng W, Guan Z, Guo Y and Han X: The
hypoxia-related signaling pathways of vasculogenic mimicry in tumor
treatment. Biomed Pharmacother. 80:127–135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Milane L, Duan Z and Amiji M: Role of
hypoxia and glycolysis in the development of multi-drug resistance
in human tumor cells and the establishment of an orthotopic
multi-drug resistant tumor model in nude mice using hypoxic
pre-conditioning. Cancer Cell Int. 11:32011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ost D, Goldberg J, Rolnitzky L and Rom WN:
Survival after surgery in stage IA and IB non-small cell lung
cancer. Am J Respir Crit Care Med. 177:516–523. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tanaka F, Yanagihara K, Otake Y, Miyahara
R, Kawano Y, Nakagawa T, Shoji T and Wada H: Surgery for non-small
cell lung cancer: Postoperative survival based on the revised
tumor-node-metastasis classification and its time trend. Eur J
Cardiothorac Surg. 18:147–155. 2000. View Article : Google Scholar : PubMed/NCBI
|
